Lixte Biotechnology Holdings, Inc. Alternatives & Competitors

12 companies similar to Lixte Biotechnology Holdings, Inc. — Lixte Biotechnology (Nasdaq: LIXT)

Cleave Therapeutics, Inc.

VCP/p97 Inhibitors for Oncology and Neurodegenerative Diseases

3 Series C $91.95M

San Francisco, United Sta...

Biopharma Biotechnology +1

Apollomics

We are a biopharmaceutical company committed to the discovery and development of mono- and...

26 Post-IPO Equity $262.60M

Foster City, United State...

Biotechnology Health Care +1

Cornerstone Pharmaceuticals

Rare Science. Rare Compassion. Rare Solutions.

Cranbury, United States

Biotechnology Pharmaceutical

Breakpoint Therapeutics

Modulating DNA damage responses to cure cancer

3 Venture round $30.00M

Hamburg, Germany

Biotechnology Health Care +1

Track all Lixte Biotechnology Holdings, Inc. competitors

Get real-time alerts when any of these companies raise funding, hire, or show growth signals.

See how it works

Treeline

Making medicines at the highest level

172 Series A $473.27M

Watertown, United States

Biotechnology Health Care +1

Antiva Biosciences, Inc.

30 Series E $140.35M

South San Francisco, Unit...

Biotechnology Health Care

7 Hills Pharma

First-in-concept platform of oral drugs to overcome immunotherapy resistance

12 Grant $23.20M

Houston, United States

Health Care Pharmaceutical

Cascadian Therapeutics, Inc.

10 Post-IPO Equity $64.90M

Seattle, United States

Biotechnology Health Care +1

Tetralogic Pharmaceuticals

10 Convertible Note $164.00M

Biotechnology Health Care +1

Semafore Pharmaceuticals

Pioneering the future of cancer treatment with innovative PI3K inhibitors.

Series B $13.50M

Biotechnology Health Care +1

GLG Pharma

Why Show the GSK Compound? Because the cancer cells become resistant. How? By STAT3! GLG's...

3 Venture round

Jupiter, United States

Biotechnology Health Care +1

Complexa

Advancing therapeutic innovation in human cell signaling for inflammation, fibrosis, and C...

Series C $86.95M

Biotechnology Health Care +1

About Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology (Nasdaq: LIXT) is a biotechnology company founded in 2004 and based in the United States. The company is focused on developing drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds to target them in animal m...

Business keywords

Lixte Biotechnology, Pharmaceuticals, Clinical-stage Company, Cancer Treatment, Drug Development, Molecular Signaling Pathways, Protein Phosphatase Inhibitors, Anti-cancer Drugs, Deacetylase Inhibitors, Neurodegenerative Diseases, DNA Damage Repair, Cell Division, Personalized Cancer Medicine, Therapeutic Compounds, Clinical Trials

Frequently Asked Questions

Companies similar to Lixte Biotechnology Holdings, Inc. include Cleave Therapeutics, Inc., Apollomics, Cornerstone Pharmaceuticals, Breakpoint Therapeutics, Treeline. They work in Biotechnology and Health Care and share Lixte Biotechnology Holdings, Inc.'s focus on drug development, cancer treatment and clinical trials.

Bounce Watch lists 12 companies that share Lixte Biotechnology Holdings, Inc.'s industries and are closest to it in business tags, services, target customers, business model and size.

Don't just read about them. Follow them.

BounceWatch watches Lixte Biotechnology Holdings, Inc. and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.

See how it works

Explore Related

Lixte Biotechnology Holdings, Inc. Profile Cleave Therapeutics, Inc. Alternatives Apollomics Alternatives Cornerstone Pharmaceuticals Alternatives All Companies All Signals Trend Reports

Compiled from the BounceWatch company index. We last looked at Lixte Biotechnology Holdings, Inc. on 12 Sep 2024. The 12 companies listed here were last checked between 26 Jul 2024 and 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.